Cipla plans to double share from consumer health business in 5 years

Transitioning brands from prescription and trade generics to over-the-counter

Cipla, the country’s third-largest pharma major, aims to more than double the contribution from consumer hea­lth business to its overall global turnover in five years. 

The consumer health business now accounts for 5-6 percent of Cipla’s overall turnover, and as Kedar Upadhye, global chief financial officer (CFO), Cipla, put it, the aim is to take that beyond 12 per cent in the next five years. 

Upadhye said, “Focus on wellness is on the rise. There is a shift from focus on illness to wellness. Our consumer health port­folio, which has strong brands like Nicotex (helps to quit smoking), Maxirich (multi­vitamin), MamaXpert (pregna­ncy